Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway in medulloblastoma

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 173-180

  He, Misi ^a   Li, Yu ^a   Zhang, Li ^a   Li, Longjiang ^a   Shen, Yi ^a   Lin, Ling ^a   Zheng, Weiping ^a   Chen, Li ^a   Bian, Xiuwu ^b   Ng, Ho Keung ^c   Tang, Li ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Curcumin; Medulloblastoma; Wnt signaling pathway; catenin

Indexed keywords

BETA CATENIN; CURCUMIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; GROWTH INHIBITION; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; WNT SIGNALING PATHWAY; APOPTOSIS; CEREBELLAR NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDULLOBLASTOMA; WNT SIGNALING PATHWAY;

EID: 84903174400     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3206     Document Type: Article

References (36)

1. de Bont JM, Packer RJ, Michiels EM, den Boer ML and Pieters R: Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol 10: 1040-1060, 2008.
2. Lin J, Zheng Y, Chen K, Huang Z, Wu X and Zhang N: Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy. Oncol Rep 30: 1739-1744, 2013.
3. Maheshwari RK, Singh AK, Gaddipati J and Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci 78: 2081-2087, 2006.
4. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: an 'old-age' disease with an 'age-old' solution. Cancer Lett 267: 133-164, 2008.
5. Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199-225, 2008.
6. Dorai T, Cao YC, Dorai B, Buttyan R and Katz AE: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47: 293-303, 2001. (Pubitemid 32521749)
7. Gilbertson RJ and Ellison DW: The origins of medulloblastoma subtypes. Annu Rev Pathol 3: 341-365, 2008. (Pubitemid 351488285)
8. Guessous F, Li Y and Abounader R: Signaling pathways in medulloblastoma. J Cell Physiol 217: 577-583, 2008.
9. Angers S and Moon RT: Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468-477, 2009.
10. Roussel MF and Hatten ME: Cerebellum development and medulloblastoma. Curr Top Dev Biol 94: 235-282, 2011.
11. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
12. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhar CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S and Taylor MD: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29: 1408-1414, 2011.
13. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A and Gilbertson RJ: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931, 2006. (Pubitemid 46638992)
14. Koch A, Hrychyk A, Hartmann W, Waha A, Mikeska T, Schuller U, Sorensen N, Berthold F, Goodyer CG, Wiestler OD, Birchmeier W, Behrens J and Pietsch T: Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer 121: 284-291, 2007. (Pubitemid 46917696)
15. Sun P, Liu Y, Ying H and Li S: Action of db-cAMP on the bystander effect and chemosensitivity through connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells. Oncol Rep 28: 969-976, 2012.
16. Wang X, Shi Q, Xu K, Gao C, Chen C, Li XL, Wang GR, Tian C, Han J and Dong XP: Familial CJD associated PrP mutants within transmembrane region induced Ctm-PrP retention in ER and triggered apoptosis by ER stress in SH-SY5Y cells. PLoS One 6: e14602, 2011.
17. Goel A, Kunnumakkara AB and Aggarwal BB: Curcumin as 'Curecumin': from kitchen to clinic. Biochem Pharmacol 75: 787-809, 2008.
18. Cole GM, Teter B and Frautschy SA: Neuroprotective effects of curcumin. Adv Exp Med Biol 595: 197-212, 2007.
19. Perry MC, Demeule M, Regina A, Moumdjian R and Beliveau R: Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 54: 1192-1201, 2010.
20. Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y, Al-Kofide A and Aboussekhra A: Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog 49: 302-314, 2010.
21. Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM and Rajasekaran SA: Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 11: 144, 2011.
22. Baryawno N, Sveinbjornsson B, Kogner P and Johnsen JI: Medulloblastoma: a disease with disorganized developmental signaling cascades. Cell Cycle 9: 2548-2554, 2010.
23. Rogers HA, Miller S, Lowe J, Brundler MA, Coyle B and Grundy RG: An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer 100: 1292-1302, 2009.
24. Baryawno N, Sveinbjornsson B, Eksborg S, Chen CS, Kogner P and Johnsen JI: Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/β-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 70: 266-276, 2010.
25. Rogers HA, Sousa S, Salto C, Arenas E, Coyle B and Grundy RG: WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer 107: 1144-1152, 2012.
26. Cimmino F, Scoppettuolo MN, Carotenuto M, De Antonellis P, Dato VD, De Vita G and Zollo M: Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/β-catenin signaling. J Neurooncol 106: 59-70, 2012.
27. Sundram V, Chauhan SC, Ebeling M and Jaggi M: Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One 7: e35368, 2012.
28. Frame S, Cohen P and Biondi RM: A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327, 2001. (Pubitemid 32607364)
29. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, Biechele T, Petryshen TL, Moon RT, Haggarty SJ and Tsai LH: Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3β/β-catenin signaling. Cell 136: 1017-1031, 2009.
30. Wu G, Huang H, Garcia Abreu J and He X: Inhibition of GSK3 phosphorylation of β-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One 4: e4926, 2009.
31. Raffel C: Medulloblastoma: molecular genetics and animal models. Neoplasia 6: 310-322, 2004.
32. Jozwiak J, Grajkowska W and Wlodarski P: Pathogenesis of medulloblastoma and current treatment outlook. Med Res Rev 27: 869-890, 2007. (Pubitemid 350035122)
33. Zhao X, Song T, He Z, Tang L and Zhu Y: A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. Med Oncol 27: 985-991, 2010.
34. Mimeault M and Batra SK: Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 62: 497-524, 2010.
35. Guoand X and Wang XF: Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res 19: 71-88, 2009.
36. Li C, Zhang Y, Lu Y, Cui Z, Yu M, Zhang S and Xue X: Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. J Cancer Res Clin Oncol 137: 771-778, 2011.